中国组织工程研究

中国组织工程研究 ›› 2010, Vol. 14 ›› Issue (32): 5967-5970.doi: 10.3969/j.issn.1673-8225.2010.32.017

• 干细胞移植 stem cell transplantation • 上一篇    下一篇

干细胞治疗自闭症:安全性和有效性观察

刘  敏1，孙良伟1，吕涌涛1，郇  英1，葛汝村2，曹毓琳3 ，郭传琴4，陈兴旺1   

  1. 山东省交通医院，1神经内科，2细胞治疗中心，山东省济南市   250031； 3深圳北科生物科技研究中心，广东省深圳市   518028；4山东省精神卫生中心，山东省济南市   250014
  • 出版日期:2010-08-06 发布日期:2010-08-06
  • 作者简介:刘敏★，女，1974年生，山东省日照市人，2007年山东大学医学院毕业，硕士，主治医师，从事脑血管病及老年期痴呆的基础与临床研究工作。 lm-jtyy@163. com

Stem cells for treatment of autism: Safety and efficacy

Liu Min1, Sun Liang-wei1, Lü Yong-tao1, Huan Ying1, Ge Ru-cun2, Cao Yu-lin3, Guo Chuan-qin4, Chen Xing-wang1   

  1. 1 Department of Neurology, Shandong Traffic Hospital, Jinan  250031, Shandong Province, China; 2 Cell Rescue Center of Shandong Traffic Hospital, Jinan  250031, Shandong Province, China; 3 Shenzhen Beike Biotechnology Research Center, Shenzhen  518028, Guangdong Province, China; 4 Shandong Mental Health Center, Jinan  250014, Shandong Province, China
  • Online:2010-08-06 Published:2010-08-06
  • About author:Liu Min★, Master, Attending physician, Department of Neurology, Shandong Traffic Hospital, Jinan 250031, Shandong Province, China lm-jtyy@163.com

PDF

719

被引次数

15

摘要：

背景：自闭症伴随许多神经生理学上的改变，特别是免疫异常和神经系统的组织灌流不足。
目的：评价干细胞治疗自闭症的可行性、安全性和有效性。
方法：42例自闭症患者随机分为脐血组、混合组和对照组，脐血组应用脐血单个核细胞治疗；混合组应用脐血单个核细胞联合脐带间充质干细胞治疗；对照组行康复训练治疗。脐血组和混合组患者治疗前和首次治疗后4周、4个月行相关指标实验室检查，并观察有无不良反应发生。3组患者在治疗前、首次治疗后4周和4个月分别行儿童自闭症评定量表(CARS)和临床总体印象量表(CGI)评估。
结果与结论：脐血组和混合组患者在治疗前和首次治疗后4周、4个月相关指标实验室检查未发现有显著异常变化，干细胞治疗后无严重不良反应发生。脐血组和混合组CARS评分在治疗前、首次治疗后4周、首次治疗后4月之间比较均明显降低，CGI量表发现混合组总有效率高于脐血组。结果提示，应用脐血单个核细胞和脐带间充质干细胞治疗自闭症是安全的，其疗效显著高于康复训练治疗。

关键词: 自闭症, 单个核细胞, 间充质干细胞, 临床评价, 安全性

Abstract:

BACKGROUND: Autism is associated with several neurophysiological alterations, especially immune abnormalities and neural hypoperfusion appear to be broadly consistent.
OBJECTIVE: To evaluate the feasibility, safety and efficacy of stem cells for treating autism.
METHODS: A total of 42 children of autism were divided into three groups: umbilical cord blood group, combination group and control group. Umbilical cord blood group was treated with umbilical cord blood mononuclear cells. Combination group was treated with umbilical cord blood mononuclear cells combined with umbilical cord mesenchymal stem cells. Control group received rehabilitation treatment. Related lab examinations were taken for umbilical cord blood and combination groups before treatment, 4 weeks after treatment and 4 months after treatment. Whether there were adverse reactions were observed. Childhood Autism Rating Scale and Clinical Global Impression Scale were employed to assess the children of autism before treatment, 4 weeks and 4 months following first treatment in patients of each group.
RESULTS AND CONCLUSION: There was no statistical difference in lab examinations between umbilical cord blood and combination groups before treatment, 4 weeks and 4 months following treatment. There were no severe adverse reactions following stem cell treatment. Childhood Autism Rating Scale was significantly decreased in the umbilical cord blood and combination groups before treatment, 4 weeks and 4 months following treatment. Clinical Global Impression Scale demonstrated that total efficiency was greater in the combination group compared with umbilical cord blood group. Results indicated that it is safe to use umbilical cord blood mononuclear cells and umbilical cord mesenchymal stem cells for treating children autism and the therapeutic effect of the umbilical cord blood and combination groups was noticeably higher than that of the control group with rehabilitation treatment.

中图分类号: